Douglas B. Johnson
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma(2016)3,493 cited
- → Fulminant Myocarditis with Combination Immune Checkpoint Blockade(2016)2,219 cited
- → Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data(2019)1,644 cited
- → Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma(2017)1,368 cited
- → Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors(2019)1,103 cited
- → Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy(2013)983 cited
- → Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis(2018)881 cited
- → Immune-checkpoint inhibitors: long-term implications of toxicity(2022)869 cited
- → Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab(2016)814 cited
- → Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors(2017)785 cited